The Place Of Mucolytics In The treatment Of Inflammatory Respiratory Diseases.

Ass. prof. G.I. Kochuev, prof. M.N. Kochueva, prof. A.N. Korzh. Kharkiv Medical Academy of Postgraduate Education.

In the work there are presened modern data on clinical effectiveness of mucolytics in the treatment of inflammatory respiratory diseases. There are described the mechanisms of impact of aciltcystein and ambroxol on mucociliary transport, as well and differentiated indications for prescription of combined drugs PulmoBriz and PulmoLor at diseases of the respiratory tract.

Key Words: inflammatory respiratory diseases, mucociliary trasport, mucolytic therapy, ambroxol, acilcystein, PulmoBriz, PulmoLor.

Kochuev GI, Kochueva MN, Korzh AN. [The Place Of Mucolytics In The treatment Of Inflammatory Respiratory Diseases]. Shidnoevr. z. vnutr. simejnoi med. 2017;1:102-107. Russian.


1. Alekseenko SN, Drobot EV. Profilaktika zabolevanii. Moscow: Akademiia Estestvoznaniia; 2015. 235p. ISBN: 978-5-91327-352-9. Russian.
2. Hogg JC, Chu F, Utokaparch S. The nature of small airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004 Jun 24;350(26):2645-53. PMID: 15215480. DOI: 10.1056/NEJMoa032158.
3. Burgel PR, Nadel JA. Epidermal growth factor receptor mediated innate immune responses and their roles in airway diseases. Eur Respir J. 2008 Oct;32(4):1068-81. DOI: 10.1183/09031936.00172007.
4. Randell SH, Boucher RC. Effective mucus clearance is essential for respiratory health. Am J Respir Cell Mol Biol. 2006 Jul; 35(1):20–28. DOI: 10.1165/rcmb.2006-0082SF
5. Innes AL, Carrington SD, Thornton DJ. Ex vivo sputum analysis reveals impairment of protease-dependent mucus degradation by plasma proteins in acute asthma. Am J Respir Crit Care Med. 2009 Aug 1;180(3):203-10. PMID: 19423716 PMCID: PMC2724713 DOI: 10.1164/rccm.200807-1056OC.
6. Rogers DF, Barnes PJ. Treatment of airway mucus hypersecretion. Ann Med. 2006;38(2):116-25. PMID: 16581697 DOI: 10.1080/07853890600585795.
7. Lethem MI, James SL, Marriott C, Burke JF. The origin of DNA associated with mucus glycoproteins in cystic fibrosis sputum. Eur Respir J. 1990 Jan;3(1):19-23. PMID: 2107097.
8. Tomkiewicz RP, Kishioka C, Freeman J, Rubin BK. DNA and actin filament ultrastructure in cystic fibrosis sputum. In: Baum GL, Priel Z, Roth Y. Cilia, mucus, and mucociliary interactions. New York: Dekker; 1998. p. 333-341.
9. Shah SA, Santago P, Rubin BK. Quantification of biopolymer filament structure. Ultramicroscopy. 2005 Oct;104(3-4):244-54. PMID: 15961231 DOI: 10.1016/j.ultramic.2005.04.007.
10. Hogg JC, Chu F, Utokaparch S. The nature of small airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004 Jun 24;350(26):2645-53. PMID: 15215480 DOI: 10.1056/NEJMoa032158.
11. James AL, Wenzel S. Clinical relevance of airway remodelling in airway diseases. Eur. Respir. J. 2007;30:134-55. PMID: 17601971 DOI: 10.1183/09031936.00146905.
12. Macklem PT, Proctor DF, Hogg JC. The stability of peripheral airways. Respir Physiol. 1970 Jan;8(2):191-203. PMID: 5413420.
13. van der Vliet A, O’Neill CA, Cross CE, Koostra JM, Volz WG, Halliwell B, Louie S. Determination of low-molecular-mass antioxidant concentrations in human respiratory tract lining fluids. Am. J. Physiol. 1999;276:289-96. PMID: 3809741
14. Moldeus P, Cotgreave IA, Berggren M. Lung protection by a thiol-containing antioxidant: N-acetylcysteine. Respiration. 1986;50:31-42.
15. Gillissen A. Characterization of N-acetylcysteine and ambroxol in antioxidant therapy. Respir Med. 1998 Apr;92(4):609-23. PMID: 9659525.
16. Beeh KM, Beier J, Esperester A, Paul LD. Antiinflammatory properties of ambroxol. Eur J Med Res. 2008 Dec 3;13(12):557-62. PMID: 19073395.
17. Malerba M, Ponticiello A, Radaeli A, Bensi G, Grassi V. Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial). Pulm Pharmacol Ther. 2004;17(1):27-34. PMID: 14643168 DOI: 10.1016/j.pupt.2003.08.004.
18. Li F, Wang W, Hu L, Li L, Yu J. Effect of ambroxol on pneumonia caused by pseudomonas aeruginosa with biofilm formation in an endotracheal intubation rat model. Chemotherapy. 2011;57(2):173-80. PubMed: 21454975 DOI: 10.1159/000323622.
19. Ottonello L, Arduino N, Bertolotto M, Dapino P, Mancini M, Dallegri F. In vitro inhibition of human neutrophil histotoxicity by ambroxol: Evidence for a multistep mechanism. Br J Pharmacol. 2003 Oct;140(4):736-42. PMID: 14534155 PMCID: PMC1574083 DOI: 10.1038/sj.bjp.0705497.
20. Zakharova IN, Korovina NA, Zaplatnikov AA. Taktika vybora i osobennosti primeneniia protivokashlevykh, otkharkivaiushchikh i mukoliticheskikh lekarstvennykh sredstv v pediatricheskoi praktike. RMZh. 2004;1:40-43. Russian.
21. Zheng CH, Ahmed K, Rikitomi N, Martinez G, Nagatake T. The effects of S-carboxymethylcysteine and N-acetylcysteine on the adherence of Moraxella catarrhalis to human pharyngeal epithelial cells. Microbiol Immunol. 1999;43(2):107-13. PMID: 10229264.
22. Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med. 1989;6(6):593-7. PMID: 2546864PMID: 2546864.
23. Morris PE, Bernard GR. Significance of glutathione in lung disease and implications for therapy. Am J Med Sci. 1994 Feb;307(2):119-27. PMID: 8141138.
24. Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther. 2000 Feb;22(2):209-21. PMID: 10743980. DOI: 10.1016/S0149-2918(00)88479-9.
25. Stey C, Steurer J, Bachmann S, Medici TC, Tramèr MR. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J. 2000 Aug;16(2):253-62. PMID: 10968500.
26. Decramer M, Rutten-van Mölken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, van Schayck CP, Olivieri D, Del Donno M, De Backer W, Lankhorst I, Ardia A. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005 Apr 30-May 6;365(9470):1552-60. PMID: 15866309. DOI: 10.1016/S0140-6736(05)66456-2.
27. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson AG, Verbeken EK, Verschakelen J, Flower CD, Capron F, Petruzzelli S, De Vuyst P, van den Bosch JM, Rodriguez-Becerra E, Corvasce G, Lankhorst I, Sardina M, Montanari M; IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005 Nov 24;353(21):2229-42. PMID: 16306520. DOI: 10.1056/NEJMoa042976.
28. Eklund A, Eriksson O, Håkansson L, Larsson K, Ohlsson K, Venge P, Bergstrand H, Björnson A, Brattsand R, Glennow C. Oral N-acetylcysteine reduces selected humoral markers of inflammatory cell activity in BAL fluid from healthy smokers: correlation to effects on cellular variables. Eur Respir J. 1988 Oct;1(9):832-8. PMID: 2852604.